Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed + Gemcitabine in Advanced Non-Clear Cell RCC
NCT00491075Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2005
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed and gemcitabine in non-clear cell renal cell carcinoma (nccRCC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Overall Response Rate at 16 weeks and Progression-Free Survival. Started Dec 2005; status: terminated.
02
Drugs
pemetrexedgemcitabine
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on NCT00491075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00491075.